Newly published results from ASX-listed diagnostics trailblazer Proteomics International Laboratories have unveiled stunning new clinical findings for its simple PromarkerEso oesophageal cancer blood test, opening the way for the innovative blood test to be commercially released.
The test’s accuracy was demonstrated in a 259-person study across three patient groups in Australia and the United States. The results were posted overnight in the peer-reviewed journal Proteomes, providing a major academic rubber stamp for the technology.
